Jinling Hospital
Nanjing, Jiangsu, China
NCT Number: NCT06405815
The investigators retrospectively collected the participants with T3 and T4, N0-2, M0 NSCLC patients resected between January 2013 to December 2021 for training and internal validation. The Clinical data, preoperative laboratory results and images were collected. High-risk margins were defined as R1 or R2 surgical margins or local recurrence during follow-up, and the investigators also collected the disease-free survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. PyRadiomics was used to extract the radiomic features. LASSO was used to select the features and tumor radiomics model, peritumor model and combined model were built using 5-fold cross-validation. And it was further tested on the independent cohort. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC), sensibility, specificity.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Nanjing, Jiangsu, China
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
extracted the tumor and peritumor radiomic feature from the preoperative enhanced chest CT
Time frame: until the December 2023
the time from the surgery time to the recurrence time
Jinling Hospital, China
Other
Development of a Tumor and Peritumor Radiomics-based Model to Predict the High-risk Surgical Margin and Prognosis of T3 and T4 Non-Small Cell Lung Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04566432
Adenocarcinoma, Adenocarcinoma of Lung
Shanghai, China
View Trial DetailsNCT04678440
Bronchial Neoplasms, Carcinoma, Bronchogenic
Sacramento, California, United States
View Trial DetailsNCT04314895
Bronchial Neoplasms, Carcinoma, Bronchogenic
Gainesville, Florida, United States
View Trial DetailsNCT04740047
Adenocarcinoma, Adenocarcinoma of Lung
Rochester, Minnesota, United States
View Trial Details